Investors of Nektar Therapeutics Stock May Have Legal Claims – NKTR
Date24 Feb 2023//
CategoriesBlog, Shareholder Investigations
Investors of Nektar Therapeutics Stock Since At Least June 2022 Encouraged to Contact Kehoe Law Firm, P.C. – Breach of Fiduciary Duties Investigation
Kehoe Law Firm, P.C. is investigating whether certain directors and officers of Nektar Therapeutics (“Nektar” or “Nektar Therapeutics”) (NASDAQ: NKTR) breached their fiduciary duties to Nektar and its shareholders.
The investigation concerns whether members of Nektar’s board of directors or senior management failed to manage Nektar Therapeutics in an acceptable manner, in breach of their fiduciary duties to Nektar, and whether Nektar Therapeutics and its shareholders have suffered damages as a result.